Teva and Sanofi duvakitug Phase 2b data show sustained efficacy in IBD
Duvakitug was well tolerated and safety was consistent with the induction study
Duvakitug was well tolerated and safety was consistent with the induction study
Ind-Ra expects chronic therapies to outpace IPM as compliance improves and lifestyle diseases rise
Operational leverage kicked in during the quarter, with adjusted EBITDA rising 21% year-on-year to Rs 147 crore
Under the deal, Uniphar will serve as LYMPHIR’s exclusive distribution partner across designated Western and Eastern European territories
BioAsia 2026 represents a decisive shift toward execution, scale, and global competitiveness, reflecting the rapid evolution of the life sciences ecosystem
Chemicals delivered improved efficiency and optimal capacity utilization, with EBIT rising 37% YoY
Launched in August 2025, GSK India’s Oncology business is rapidly gaining momentum
The therapy is currently completing Phase 1 clinical trials in renal cell carcinoma and non-small cell lung cancer
Subscribe To Our Newsletter & Stay Updated